FDA-Approved Drugs Efavirenz, Tipranavir, and dasabuvir Inhibit Replication of Multiple Flavivures in Vero Cels

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00027162%3A_____%2F20%3AN0000104" target="_blank" >RIV/00027162:_____/20:N0000104 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.mdpi.com/2076-2607/8/4/599" target="_blank" >https://www.mdpi.com/2076-2607/8/4/599</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/microorganisms8040599" target="_blank" >10.3390/microorganisms8040599</a>

Jazyk výsledku

angličtina

Název v původním jazyce

FDA-Approved Drugs Efavirenz, Tipranavir, and dasabuvir Inhibit Replication of Multiple Flavivures in Vero Cels

Popis výsledku v původním jazyce

Vector-borne flaviviruses (VBFs) affect human health worldwide, but no approved drugs are available specifically to treat VBF-associated infections. Here, we performed in silico screening of a library of U.S. Food and Drug Administration-approved antiviral drugs for their interaction with Zika virus proteins. Twelve hit drugs were identified by the docking experiments and tested in cell-based antiviral assay systems. Efavirenz, tipranavir, and dasabuvir at micromolar concentrations were identified to inhibit all VBFs tested; i.e., two representatives of mosquito-borne flaviviruses (Zika and West Nile viruses) and one representative of flaviviruses transmitted by ticks (tick-borne encephalitis virus). The results warrant further research into these drugs, either individually or in combination, as possible pan-flavivirus inhibitors.

Název v anglickém jazyce

FDA-Approved Drugs Efavirenz, Tipranavir, and dasabuvir Inhibit Replication of Multiple Flavivures in Vero Cels

Popis výsledku anglicky

Vector-borne flaviviruses (VBFs) affect human health worldwide, but no approved drugs are available specifically to treat VBF-associated infections. Here, we performed in silico screening of a library of U.S. Food and Drug Administration-approved antiviral drugs for their interaction with Zika virus proteins. Twelve hit drugs were identified by the docking experiments and tested in cell-based antiviral assay systems. Efavirenz, tipranavir, and dasabuvir at micromolar concentrations were identified to inhibit all VBFs tested; i.e., two representatives of mosquito-borne flaviviruses (Zika and West Nile viruses) and one representative of flaviviruses transmitted by ticks (tick-borne encephalitis virus). The results warrant further research into these drugs, either individually or in combination, as possible pan-flavivirus inhibitors.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10613 - Zoology

Projekt

<a href="/cs/project/EF15_003%2F0000495" target="_blank" >EF15_003/0000495: FIT (Farmakologie, Imunoterapie, nanoToxikologie)</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

MICROORGANISMS

ISSN

2076-2607

e-ISSN

2076-2607

Svazek periodika

8

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

17

Strana od-do

"599"

Kód UT WoS článku

000533510400128

EID výsledku v databázi Scopus

2-s2.0-85084005221